Rhythm Pharmaceuticals to Report Third Quarter 2026 Financial Results on Tuesday, November 3, 2026GlobeNewsWire · 3 days ago
Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic ObesityGlobeNewsWire · Oct 13, 2026
Rhythm Pharmaceuticals (RYTM) Upgraded to Buy: Here's What You Should KnowZacks Investment Research · Oct 13, 2026
Kuehn Law Encourages Investors of Rhythm Pharmaceuticals, Inc. to Contact Law FirmPRNewsWire · Sep 28, 2026
Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® (setmelanotide) for Weight Management in Adult and Pediatric Patients 4 years of Age and Older with Acquired Hypothalamic ObesityGlobeNewsWire · Sep 22, 2026
David Meeker Sells 50,000 Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) StockDefense World · Sep 16, 2026Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$0.81 | -$0.73 | Beat |
| May 5, 2026 | -$0.86 | -$0.83 | Beat |
| Feb 26, 2026 | -$0.79 | -$0.73 | Beat |
| Nov 4, 2025 | -$0.72 | -$0.82 | Miss |
| Aug 5, 2025 | -$0.66 | -$0.75 | Miss |
| May 7, 2025 | -$0.69 | -$0.81 | Miss |